Navigation Links
Varian Medical Systems and Stanford University Win $3.6 Million Five-Year NIH/NCI Research Grant to Develop Advanced Imaging Technology

PALO ALTO, Calif., Oct. 11 /PRNewswire/ -- Scientists from Stanford University and from the Ginzton Technology Center at Varian Medical Systems have jointly received a $3.6 million five-year research grant from the U.S. National Institutes of Health (NIH) to develop advanced imaging technology for improving the quality of CT images for patients with metal objects in their bodies such as hip implants and dental fillings.  

The grant award is from the Cancer Imaging Program (CIP) of the National Cancer Institute (NCI) within NIH. The CIP made the grant under its program entitled: Academic-Industrial Partnerships for Development and Validation of In Vivo Imaging Systems and Methods for Cancer Investigations, which was set up to encourage inter-disciplinary research by industry and academia into cancer-related imaging challenges. Josh Star-Lack, Ph.D., a senior scientist in Varian's Ginzton Technology Center for research and development, and Rebecca Fahrig, Ph.D., associate professor of radiological sciences at the Stanford University School of Medicine, will serve as co-principal investigators on the project.  

"Modern radiotherapy of cancer often relies on high quality CT images for planning advanced forms of treatment," said Star-Lack.  "You also need good cone-beam CT images from a machine-mounted imager for patient positioning and for assessing tumor response to treatment.  These CT images are typically acquired at kilovoltage X-ray energies resulting in excellent soft tissue definition, which means you can distinguish tumor from muscle, fat, or other organs. Unfortunately, severe image distortions can be created when metal is present, making it harder to know what you're looking at."

According to Star-Lack, it is possible to greatly reduce the distortions by using very high energy (megavoltage) x-rays that better penetrate the metal.  However, megavoltage imaging also has significant disadvantages.  "You need a lot of dose, and the quality of images is poor, particularly in soft tissues," Star-Lack said.  "Our research grant will be used to develop tools to achieve the best of both worlds by combining kilovoltage cone-beam CT data with a limited amount of megavoltage data to create a composite image with less distortion and good soft tissue resolution."

As part of the project, researchers from Varian and Stanford will develop new megavoltage X-ray detection hardware and image reconstruction software, and will validate the new technology in a clinical trial to be conducted by Stanford.

"The rapid translation of these advances into clinical practice could improve the accuracy of radiotherapy planning and image guidance for patients with metal objects near the targeted tumors," Fahrig said.  "This is a unique grant program that recognizes the special synergies that can happen when academic researchers, who often focus on pure science, collaborate with industrial researchers, who often emphasize product-oriented R&D with near-term commercial possibilities."

The Ginzton Technology Center (GTC) serves as Varian Medical Systems' central R&D organization, incubating new technologies, supporting product development for the company's business units, and conducting government or industry-sponsored research projects. The GTC's mandate is to focus on the investigation of development of new, disruptive, "breakout" technologies that will create significantly improved capabilities for Varian's customers.

About Varian Medical SystemsVarian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,200 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit Medical SystemsMeryl Ginsberg,

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Therapeutic Drug Monitoring (TDM) ... Competitive Intelligence, Emerging Opportunities"  report to ... ) has announced the addition of ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Italian ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
Breaking Medicine Technology:
(Date:11/26/2015)... Las Vegas, NV (PRWEB) , ... November 26, 2015 , ... ... holiday shopping strategy. Many customers choose to buy during the Black Friday and ... holiday gifts. Shoppers don’t need to search the Internet high and low to find ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied ... the need to integrate dose form selection in early phase drug development. The ... organization supporting and bringing together the UK’s emerging life sciences companies, corporate partners, ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., the first ... annual Employee Benefits Conference. The Employee Benefits Conference was hosted by the International ... November 11th, 2015. The conference was held at the Hawaii Convention Center in ...
(Date:11/26/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the world-class Asterisk based ... efficiency and reliability. , The new Q-Suite 6 platform is based on the latest ... itself into a specific piece of software for many key components of the suite. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the perfect dish and pleasing the palates of attendees is of the utmost ... dish to a seasonal get-together, give these recipes a try this holiday season. ...
Breaking Medicine News(10 mins):